190 related articles for article (PubMed ID: 9425399)
1. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
Broson-Chazot F; Houzard C; Ajzenberg C; Nocaudie M; Duet M; Mundler O; Marchandise X; Epelbaum J; Gomez De Alzaga M; Schäfer J; Meyerhof W; Sassolas G; Warnet A
Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
[TBL] [Abstract][Full Text] [Related]
2. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
[TBL] [Abstract][Full Text] [Related]
3. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
4. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index.
Duet M; Mundler O; Ajzenberg C; Berolatti B; Chedin P; Duranteau L; Warnet A
Eur J Nucl Med; 1994 Jul; 21(7):647-50. PubMed ID: 7957351
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
Duet M; Ajzenberg C; Benelhadj S; Lajeunie E; Lormeau B; Guillausseau PJ; Rohmer V; Vilain D; Mundler O; Warnet A
J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor scintigraphy in patients with pituitary adenoma.
Rieger A; Rainov NG; Elfrich C; Klaua M; Meyer H; Lautenschläger C; Burkert W; Mende T
Neurosurg Rev; 1997; 20(1):7-12. PubMed ID: 9085281
[TBL] [Abstract][Full Text] [Related]
8. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.
Legovini P; De Menis E; Billeci D; Conti B; Zoli P; Conte N
J Endocrinol Invest; 1997; 20(7):424-8. PubMed ID: 9309542
[TBL] [Abstract][Full Text] [Related]
9. [Prediction of pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index].
Görges R; Cordes U; Engelbach M; Bartelt KM; Haberern G; Hey O; Beyer J; Bockisch A
Nuklearmedizin; 1997 Jun; 36(4):117-24. PubMed ID: 9289697
[TBL] [Abstract][Full Text] [Related]
10. 111In-octreotide scintigraphy in pituitary adenomas.
Tofani A; Cucchi R; Pompili A; Carapella C; Crecco M; Mottolese M; Maini CL
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):94-7. PubMed ID: 9002760
[TBL] [Abstract][Full Text] [Related]
11. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
[TBL] [Abstract][Full Text] [Related]
12. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro.
de Bruin TW; Kwekkeboom DJ; Van't Verlaat JW; Reubi JC; Krenning EP; Lamberts SW; Croughs RJ
J Clin Endocrinol Metab; 1992 Nov; 75(5):1310-7. PubMed ID: 1430093
[TBL] [Abstract][Full Text] [Related]
13. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.
Oppizzi G; Cozzi R; Dallabonzana D; Orlandi P; Benini Z; Petroncini M; Attanasio R; Milella M; Banfi G; Possa M
J Endocrinol Invest; 1998 Sep; 21(8):512-9. PubMed ID: 9801992
[TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
15. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide.
Ezzat S; Kontogeorgos G; Redelmeier DA; Horvath E; Harris AG; Kovacs K
Eur J Endocrinol; 1995 Dec; 133(6):686-90. PubMed ID: 8548053
[TBL] [Abstract][Full Text] [Related]
16. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy.
Lamberts SW; Hofland LJ; de Herder WW; Kwekkeboom DJ; Reubi JC; Krenning EP
Front Neuroendocrinol; 1993 Jan; 14(1):27-55. PubMed ID: 8097480
[TBL] [Abstract][Full Text] [Related]
17. Prediction of efficacy of octreotide therapy in patients with acromegaly.
Colao A; Ferone D; Lastoria S; Marzullo P; Cerbone G; Di Sarno A; Longobardi S; Merola B; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2356-62. PubMed ID: 8964877
[TBL] [Abstract][Full Text] [Related]
18. Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma.
George SR; Kovacs K; Asa SL; Horvath E; Cross EG; Burrow GN
Clin Endocrinol (Oxf); 1987 Apr; 26(4):395-405. PubMed ID: 2888549
[TBL] [Abstract][Full Text] [Related]
19. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels.
Losa M; Magnani P; Mortini P; Persani L; Acerno S; Giugni E; Songini C; Fazio F; Beck-Peccoz P; Giovanelli M
Eur J Nucl Med; 1997 Jul; 24(7):728-31. PubMed ID: 9211757
[TBL] [Abstract][Full Text] [Related]
20. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
